香港股市 已收市

Cronos Group Inc. (CRON)

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
2.42000.0000 (0.00%)
收市:04:00PM EDT
2.4500 +0.03 (+1.24%)
收市後: 07:44PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價2.4200
開市2.4300
買盤2.4100 x 700
賣出價2.4400 x 900
今日波幅2.4037 - 2.4500
52 週波幅1.6400 - 3.1400
成交量401,563
平均成交量1,811,793
市值924.467M
Beta 值 (5 年,每月)1.01
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-0.1400
業績公佈日2024年8月08日
遠期股息及收益率無 (無)
除息日
1 年預測目標價2.62
  • InvestorPlace

    7 Millionaire-Making Growth Stocks to Buy and Forget

    Before entering the markets, investors need to clearly define their objective. If the idea is to take low-risk and beat inflation, it makes sense to go overweight on blue-chip stocks trading at attractive valuations. If the idea is to generate regular cash flows, investors should be overweight on high dividend yield stocks. Additionally, if the idea is to make massive wealth from the markets, the only way is exposure to millionaire-maker growth stocks. This column focuses on growth stocks to buy

  • InvestorPlace

    3 Growth Stocks Under $5 to Buy Today

    In the middle of a bull market, it is difficult to find good, cheap growth stocks. While you could dig amongst penny stocks to find something to buy, they tend to carry too much risk. More often than not they have a story to tell but no real products or services to sell. Yet raise your sights just a little and you can find growth stocks under $5 that you can buy today. They are accomplished businesses with a proven (or provable) track record. They might not be profitable but there is a clear roa

  • InvestorPlace

    3 Cannabis Stocks That Could Grow Your Wealth

    The performance of cannabis stocks has been underwhelming in the last few years. The reasons include regulatory headwinds, intense competition, and sustained cash burn. However, there finally seems to be light at the end of the tunnel. First, regulatory headwinds seem to be gradually waning. Earlier this year, Germany legalized cannabis for recreational use. Further, the reclassification of cannabis as a Schedule III drug is impending in the United States. It’s also worth noting that some of the